MXPA99006961A - Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator - Google Patents
Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiatorInfo
- Publication number
- MXPA99006961A MXPA99006961A MXPA/A/1999/006961A MX9906961A MXPA99006961A MX PA99006961 A MXPA99006961 A MX PA99006961A MX 9906961 A MX9906961 A MX 9906961A MX PA99006961 A MXPA99006961 A MX PA99006961A
- Authority
- MX
- Mexico
- Prior art keywords
- chemotherapeutic agent
- medicament
- kit according
- agents
- benzimidazole
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 35
- 201000011510 cancer Diseases 0.000 title claims abstract description 35
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 230000002401 inhibitory effect Effects 0.000 title abstract description 9
- 241000124008 Mammalia Species 0.000 claims abstract description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 230000037396 body weight Effects 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 13
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 12
- TWFZGCMQGLPBSX-UHFFFAOYSA-N carbendazim Chemical compound C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 claims description 11
- -1 nitro, methyl Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 102000004243 Tubulin Human genes 0.000 claims description 8
- 108090000704 Tubulin Proteins 0.000 claims description 8
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 claims description 7
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 6
- 230000000340 anti-metabolite Effects 0.000 claims description 6
- 239000002256 antimetabolite Substances 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 230000001603 reducing Effects 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 5
- 229940079593 drugs Drugs 0.000 claims description 5
- 229960001330 hydroxycarbamide Drugs 0.000 claims description 5
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims description 5
- 229940027318 hydroxyurea Drugs 0.000 claims description 5
- 239000002502 liposome Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims description 5
- 229960003272 ASPARAGINASE Drugs 0.000 claims description 4
- 102000015790 Asparaginase Human genes 0.000 claims description 4
- 108010024976 Asparaginase Proteins 0.000 claims description 4
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 4
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 3
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001561 Bleomycin Drugs 0.000 claims description 3
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- 229960004397 Cyclophosphamide Drugs 0.000 claims description 3
- 229960000684 Cytarabine Drugs 0.000 claims description 3
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 3
- 229960000640 Dactinomycin Drugs 0.000 claims description 3
- 108010092160 Dactinomycin Proteins 0.000 claims description 3
- 229960004679 Doxorubicin Drugs 0.000 claims description 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 3
- 229960005420 Etoposide Drugs 0.000 claims description 3
- 229960001278 Teniposide Drugs 0.000 claims description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 229960000473 altretamine Drugs 0.000 claims description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 229960002756 Azacitidine Drugs 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- LTKHPMDRMUCUEB-IBGZPJMESA-N CB3717 Chemical compound C=1C=C2NC(N)=NC(=O)C2=CC=1CN(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 LTKHPMDRMUCUEB-IBGZPJMESA-N 0.000 claims description 2
- 229960000961 Floxuridine Drugs 0.000 claims description 2
- 229960002949 Fluorouracil Drugs 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 229960001592 Paclitaxel Drugs 0.000 claims description 2
- 229960002340 Pentostatin Drugs 0.000 claims description 2
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 2
- 229960005454 Thioguanine Drugs 0.000 claims description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 2
- 229960001428 mercaptopurine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229930003347 taxol Natural products 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 35
- 150000001556 benzimidazoles Chemical class 0.000 abstract description 16
- 239000000203 mixture Substances 0.000 abstract description 15
- 150000001875 compounds Chemical class 0.000 description 18
- 210000004027 cells Anatomy 0.000 description 12
- XYWJNTOURDMTPI-UHFFFAOYSA-N 3-(1H-benzimidazol-1-ium-2-yl)propanoate Chemical compound C1=CC=C2NC(CCC(=O)O)=NC2=C1 XYWJNTOURDMTPI-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 230000002708 enhancing Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 6
- 239000002168 alkylating agent Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000006013 carbendazim Substances 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 229940088597 Hormone Drugs 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010059512 Apoptosis Diseases 0.000 description 3
- 102000028664 Microtubules Human genes 0.000 description 3
- 108091022031 Microtubules Proteins 0.000 description 3
- 210000004688 Microtubules Anatomy 0.000 description 3
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 3
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229950000989 procodazole Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 210000004881 tumor cells Anatomy 0.000 description 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N Cortisol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229960003180 Glutathione Drugs 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- CBEQULMOCCWAQT-WOJGMQOQSA-N Triprolidine Chemical group C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000001919 adrenal Effects 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 230000000172 allergic Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 230000000973 chemotherapeutic Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 230000003054 hormonal Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229960001128 triprolidine Drugs 0.000 description 2
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N 17-Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229960003437 Aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960001220 Amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- 229960005261 Aspartic Acid Drugs 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- RIOXQFHNBCKOKP-UHFFFAOYSA-N Benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 1
- 229960002747 Betacarotene Drugs 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 1
- 229960001334 Corticosteroids Drugs 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 108009000097 DNA Replication Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N Diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229940088598 Enzyme Drugs 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229940011871 Estrogens Drugs 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Etivex Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N Flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229940014144 Folate Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 229960003690 Goserelin Acetate Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- 229940040129 Luteinizing Hormone Drugs 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N Medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- VHRSUDSXCMQTMA-PJHHCJLFSA-N Methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 229940030484 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM ESTROGENS Drugs 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- 229960001712 Testosterone Propionate Drugs 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 229960004546 Thiabendazole Drugs 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N Tiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 206010047461 Viral infection Diseases 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 229940045997 Vitamin A Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 229940046009 Vitamin E Drugs 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopro Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IKDXDQDKCZPQSZ-JHYYTBFNSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000003388 anti-hormone Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 229940058303 antinematodal Benzimidazole derivatives Drugs 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- OENHQHLEOONYIE-VYAWBVGESA-N beta-Carotene Natural products CC=1CCCC(C)(C)C=1\C=C\C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-VYAWBVGESA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000000711 cancerogenic Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 229920002083 cellular DNA Polymers 0.000 description 1
- 229920002092 cellular RNA Polymers 0.000 description 1
- 210000003850 cellular structures Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940035811 conjugated estrogens Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000000445 cytocidal Effects 0.000 description 1
- 231100000409 cytocidal Toxicity 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940046080 endocrine therapy drugs Estrogens Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 230000002480 immunoprotection Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- OSFNNBOXQCLGKZ-UHFFFAOYSA-N methyl N-[4-(butylcarbamoyl)-1H-benzimidazol-2-yl]carbamate Chemical compound CCCCNC(=O)C1=CC=CC2=C1NC(NC(=O)OC)=N2 OSFNNBOXQCLGKZ-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 230000003362 replicative Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Abstract
A method for inhibiting the growth of tumors and cancers in mammals comprising administering a chemotherapeutic agent to significantly reduce the tumor in mass and then administering a benzimidazole derivative. Potentiators can also be included in the benzimidazole composition.
Description
CASE TO INHIBIT THE GROWTH OF CANCERES, WHICH
UNDERSTANDS A CHEMOTHERAPEUTIC AGENT AND A
BENCIMIDAZOL, AND OPTIONALLY A POTENTIAL
TECHNICAL FIELD The present invention relates to a method for inhibiting the growth of cancers and tumors in mammals. Particularly in humans and warm-blooded animals. The method involves the sequential administration of chemotherapeutic agents that reduce tumor size, and a benzimidazole derivative, preferably carbendazim or 2-methoxycarbonylaminobenzimidazole, in any order.
BACKGROUND OF THE INVENTION Cancers are a leading cause of death in animals and humans. The exact cause of the cancer is not known, but the relationships between certain activities such as smoking or exposure to carcinogens and the incidence of certain types of cancers and tumors have been demonstrated by a number of researchers. It has been shown that many types of chemotherapeutic agents are effective against cancers and tumor cells, but unfortunately, many of these agents also destroy normal cells. Despite advances in the field of cancer treatment, the main therapies to date are surgery, radiation and chemotherapy. The chemotherapeutic approaches are said to fight cancers that have metastases, or some that are particularly aggressive. Such cytocidal or cytostatic agents work best on cancers with large growth factors, ie, those whose cells are dividing rapidly. The exact mechanism for the action of these chemotherapeutic agents is not always known. On the other hand, while some chemotherapeutic agents reduce tumor mass significantly, after treatment, unfortunately they can not be administered again to the same patient when the tumor returns, as is usually the case. Some can only be administered once in the course of a life, others require a delay of several mo or years between treatments. Clearly, the development of materials targeting tumor cells due to some specificity unique to them would be an important discovery. Alternatively, materials that were cytotoxic to tumor cells while exerting mild effects on normal cells would be desirable. It has been found that benzimidazoles are especially effective in suppressing the growth of cancers and tumors. The use of these benzimidazoles in sequential combination with other chemotherapeutic agents that are effective in decreasing tumor volume is a novel treatment method. The preferred method involves first reducing the volume or reducing the tumor mass with a cytotoxic agent, and then administering the benzyl idazole. It is an object of this invention to provide an anti-cancer therapy comprising administering a chemotherapeutic agent first, to reduce the tumor mass, and then administering a benzimidazole derivative defined herein, to maintain or destroy the cancer. The agents can also be administered with the benzimidazole first and then the chemotherapeutic agent. The benzimidazole can be administered in conjunction with an enhancer.
These and other objects will become apparent from the following detailed description of the invention.
BRIEF DESCRIPTION OF THE INVENTION The present invention describes a method for treating cancer in mammals, and in particular, warm-blooded and human animals, which comprises administering a chemotherapeutic agent that significantly reduces the mass of the tumor or cancer, and then administering a safe and effective amount of a benzimidazole selected from the group consisting of:
wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms, or alkoxy of less than 7 carbon atoms; n is a positive integer less than 4; And it is hydrogen, chlorine, nitro, methyl or ethyl; and R is hydrogen, or an alkyl group of 1 to 8 carbon atoms, or CONHR3, and R3 is alkyl of less than 7 carbon atoms, preferably butyl or isobutyl, and R2 is 4-thiazolyl, NHCOORi, wherein Ri is an aliphatic hydrocarbon of less than 7 carbon atoms, and preferably an alkyl group of less than 7 carbon atoms. Preferably the compositions are:
wherein R is hydrogen or C0NHR3, and R3 is alkyl of less than 7 carbon atoms, preferably butyl or isobutyl, or an alkyl of 1 to 8 carbon atoms, and R2 is selected from the group consisting of 4-thiazolyl, or NHCOORi, wherein Ri is methyl, ethyl or isopropyl, and the non-toxic, pharmaceutically acceptable acid addition salts with both organic and inorganic acids. The most preferred compounds are 2- (4-thiazolyl) enimidazole, methyl- (butylcarbaoyl) -2-benzimidazolcarbamate and 2-methoxycarbonylamino-benzimidazole, and those wherein Y is chloro. These compositions can be used to inhibit the growth of cancers and other tumors in humans or animals, by the administration of an effective amount either orally, rectally, topically or parenterally, intravenously or by injection into the tumor. Enhancers with this composition can also be used.
DETAILED DESCRIPTION OF THE INVENTION A. DEFINITIONS As used herein, the term "comprises" means that various components can be used together in the pharmaceutical composition of this invention. Accordingly, the terms "consists essentially of" and "consists of" are incorporated in the term comprises. As used herein, a "pharmaceutically acceptable" component is one that is suitable for use with humans and / or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) in proportion to a benefit / benefit ratio. reasonable risk. As used herein, the term
"safe and effective amount" refers to the amount of a component that is sufficient to provide a desired therapeutic response without undue adverse side effects (such as toxicity, irritation, and allergic response) in proportion to a reasonable benefit / risk ratio, when it is used in the manner of this invention. The specific "safe and effective amount" will obviously vary with factors such as the particular condition being treated, the physical condition of the patient, the type of mammal being treated, the duration of the treatment, the nature of the concurrent therapy (if any), and the specific formulations used, and the structure of the compounds or their derivatives. As used herein, a "pharmaceutical addition salt" is a salt of the benzimidazoles and their derivatives with an organic or inorganic acid. These preferred acid addition salts are chlorides, bromides, sulfates, nitrates, phosphates, sulfonates, formations, tartrates, maleates, maleates, citrates, benzoates, salicylates, ascorbates, and the like. As used herein, a "pharmaceutical carrier" is a pharmaceutically acceptable solvent, suspending agent, or vehicle, including liposomes, for delivering the anti-cancer agent to the animal or human. The carrier can be liquid or solid, and is selected with the manner of administration planned in mind.
As used herein, "cancer" refers to all types of cancers or neoplasms or malignancies found in mammals, including tumors and leukemias. As used herein, the
"Benzimidazoles, and their salts" are described in detail below. Preferred materials are the products sold under the names "thiabendazole ™," "benomyl" and "carbendazim" by BASF and Hoechst, Du Pont and MSD-AgVet. As used herein, "chemotherapeutic agents" includes agents that interact with DNA, antimetabolites or agents that interact with tubulin, hormonal agents, and others, such as asparaginase or hydroxyurea. As used herein, "enhancers" are materials such as tripolidine and its cis isomer and procodazole, which are used in combination with chemotherapeutic agents and benzimidazoles. As used herein, "significantly reduces" means reducing the tumor mass by a significant amount. This will usually be less than 50% of its original mass, and preferably reduce the mass to undetectable amounts.
B. BENZMIDAZOLE COMPOUNDS Benzimidazole derivatives are known for their antifungal activity. Surprisingly it has been found that these compounds can also cause apoptosis in cancer cell lines. Apoptosis is the specific cell death that differs from necrosis. The majority of cancer cells can live indefinitely; Cancer cells are often referred to as immortalized cell lines. Therefore, the ability to induce apoptosis is very important. The compounds have the following structure:
wherein X is hydrogen, halogen, alkyl of less than 7 carbon atoms, or alkoxy of less than 7 carbon atoms; n is a positive integer less than 4; And it is hydrogen, chlorine, nitro, methyl or ethyl; and R is hydrogen, or C0NHR3, and R3 is alkyl of less than 7 carbon atoms, preferably butyl or isobutyl, or an alkyl group having from 1 to 8 carbon atoms, and R2 is 4-thiazolyl, or NHCOORi, in where Ri is an aliphatic hydrocarbon of less than 7 carbon atoms, and preferably an alkyl group of less than 7 carbon atoms. Preferably the compositions are:
wherein R is hydrogen or C0NHR3, and R3 is alkyl of less than 7 carbon atoms, preferably butyl or isobutyl, or an alkyl of 1 to 8 carbon atoms, and R2 is selected from the group consisting of 4-thiazolyl, or NHCOORi, wherein Ri is methyl, ethyl or isopropyl, and the non-toxic, pharmaceutically acceptable acid addition salts with both organic and inorganic acids. The most preferred compounds are 2- (4-thiazolyl) enimidazole, methyl- (butylcarbamoyl) -2-benzimidazolcarbamate and 2-methoxycarbonylamino-benzimidazole, and the compounds wherein Y is chloro and X is hydrogen. These compounds are prepared according to the method described in U.S. No. 3, 738,995, assigned to Ada s et al., June 12, 1973. Thiazolyl derivatives are prepared according to the method described in Brown et al., J. Am. Chem. Soc, 83, 1764 (1961) and Grenda et al. J. Org. Chem. 30, 259, (1965).
C. CHEMOTHERAPEUTIC AGENTS Chemotherapeutic agents are generally grouped as agents that interact with DNA, antimetabolites, agents that interact with tubulin, hormonal agents, and others such as asparaginase or hydroxyurea. Each of the groups of chemotherapeutic agents can be further divided by the type of activity or compound. The chemotherapeutic agents used in the sequential method in combination with benzimidazoles include primarily members of the groups of agents that interact with DNA, antimetabolites, agents that interact with tubulin. For a detailed discussion of chemotherapeutic agents and their method of administration, see Dorr, et al., Cancer Chemotherapy Handboo, 2a. edition, pages 15-34, Appleton & Lange (Connecticut, 1994) incorporated herein by reference.
To reduce the mass of the tumor or stop the growth of the cancer cells, the chemotherapeutic agent must prevent the cells from replicating, and must also interfere with the ability of the cells to maintain themselves. The agents that do this are primarily the agents that interact with DNA, such as Cisplatin, and the agents that interact with tubulin. Agents that interact with DNA include alkylating agents, for example Cisplatin, Cyclophosphamide, Altretamine; the breaking agents of the DNA strand, such as Bleomycin; inhibitors that are intercalated with topoisomerase II, for example Dactinomycin and Doxorubicin); inhibitors that do not intercalate from topoisomerase II such as Etoposide and Teniposide; and the binder of the minor groove of the Plcamidin DNA. Alkylating agents form covalent chemical adducts with cellular DNA and RNA, and with smaller protein and amino acid molecules, glutathione and similar chemical compounds. Generally, these alkylating agents react with a nucleophilic atom in a cellular constituent, such as an amino, carboxyl, phosphate, sulfhydryl group in nucleic acids, proteins, amino acids, or glutathione. The mechanism and role of these alkylating agents in cancer therapy are not very well understood. Typical alkylating agents include: Nitrogenated mustards, such as Chlora bucil, Cyclophosphamide, Isofamide,
Mechlorethamine, Melphalan, Uracil mustard; aziridines such as Tiotepa; phonate metansul esters such as
Busulfan; nitrous ureas, such as Carmustine, Lomustine, Streptozocin; platinum complexes, such as Cisplatin, Carboplatin; biorreductive alkylating agents, such as Mitomycin, and Procarbazine, Dacarbazine and Altretamine; DNA strand break agents that include Bleomycin; inhibitors of DNA topoisomerase II including the following: Intercalators, such as Amsacrine, Dactinomycin, Daunorubicin, Doxorubicin, Idarubicin and Mitoxantrone;
Non-intercalary, such as Etoposide and Teniposide. The binder of the minor groove of DNA is Plicamycin. Antimetabolites interfere with the production of nucleic acids by one or the other of two main mechanisms. Some of the drugs inhibit the production of deoxyribonucleoside triphosphates, which are the immediate precursors for DNA synthesis, thereby inhibiting DNA replication. Some of the compounds are sufficiently similar to purines or pyrimidines to be able to substitute them in the anabolic pathways of the nucleotide. These analogs can then be replaced within the DNA and RNA instead of their normal counterparts. Antimetabolites useful herein include: folate antagonists such as methotrexate and trimetrexate, pyrimidine antagonists, such as
Fluorouracil, Fluorodeoxyuridine, CB3717, Azacitidine, Cytarabine, and Floxuridine. purine antagonists including mercaptopurine, 6-thioguanine, fludarabine, and pentostatin;
modified sugar analogues, which include cyctrabin, fludarabine; inhibitors of ribonucleotide reductase including hydroxyurea. The agents that interact with tubulin act by binding to specific sites on tubulin, a protein that polymerizes to form cellular microtubules. Microtubules are critical units of the cellular structure. When interactive agents bind on the protein, the cell can not form microtubules. Agents that interact with tubulin include vincristine and vinblastine, both alkaloids, and paclitaxel. Adrenal cortical corticosteroids are derived from natural adrenal cortisol or hydrocortisone. They are used because of their anti-inflammatory benefits, as well as the ability of some to inhibit mitotic divisions and interrupt DNA synthesis. These compounds include prednisone, dexamethasone, methylprednisolone, and prednisolone. Hydroxyurea appears to act primarily through the inhibition of the enzyme ribonucleotide reductase.
Asparaginase is an enzyme that converts asparagine into non-functional aspartic acid and thus blocks the synthesis of proteins in the tumor. Hormone agents and luteinizing hormones are not usually used to substantially reduce the mass of the tumor. However, they can be used in conjunction with chemotherapeutic agents or benzimidazoles. Hormone blocking agents are also useful in the treatment of cancers and tumors.
They are used in hormonally susceptible tumors, and are usually derived from natural sources. These include: estrogens, conjugated estrogens and ethinyl estradiol and diethylstilbestrol, chlorotrianiseno and idenestrol; progestins such as hydroxyprogesterone caproate, medroxyprogesterone, and mage trol; androgens such as testosterone, testosterone propionate; fluoximestrone, methyl tert-butyl; Hormone agents that release luteinizing hormone or hormone antagonists that release gonadotropin are used primarily for the treatment of prostate cancer. These include leuprolide acetate and goserelin acetate.
They prevent the biosynthesis of steroids in the testicles. Antihormonal antigens include: antiestrogenic agents such as
Tamosifen, antiandrogen agents such as flutamide; and anti-adrenal agents such as mitotane and aminoglutethimide.
D. POTENTIATORS "Enhancers" can be any material that improves or increases the efficacy of the pharmaceutical composition and / or acts on the immune system. One enhancer is triprolidine and its cis isomer, which are used in combination with chemotherapeutic agents and benzimidazole. Triprolidine is described in US No. 5,114,951 (1992). Another enhancer is procodazole, 1H-benzimidazole-2-propanoic acid; [β- (2-benzimidazole) propionic acid; and 2- (2-carboxyethyl) -benzimidazole; propazole]. Procodazole is a non-specific active immunoprotective agent against viral and bacterial infections, and may be used with the compositions claimed herein. The enhancers can improve the efficacy of the benzimidazole compounds, and can be used in a safe and effective amount. These combinations can be administered to the patient or animal by oral, rectal, topical or parenteral administration. Antioxidant vitamins such as ascorbic acid, beta-carotene, vitamin A and vitamin E can be administered with the compositions of this invention.
E. DOSAGE Any suitable dosage can be given in the method of the invention. The type of compounds and carriers and the amount will vary widely, depending on the species of the warm-blooded or human animal, body weight, and cancer, or tumor being treated. The range and relationship of the chemotherapeutic agent and the benzimidazoles and their derivatives used will depend on the type of chemotherapeutic agent and the cancer being treated. Generally, for benzimidazoles a dosage of between about 2 milligrams (mg) per kilogram (kg) of body weight and about 4000 mg per kg of body weight is adequate. Higher dosages, up to 6000 mg / kg, can also be used. Preferably, from 15 mg to about 3000 mg / kg of body weight is used for the benzimidazoles. For chemotherapeutic agents, a lower dosage may be appropriate, that is, from about 0.01 mg / kg of body weight to about 400 mg / kg of body weight, although amounts of up to 1500 mg / kg of body weight may be used. . Generally, the dosage in man is lower than for small warm-blooded mammals, such as mice. A dosage unit may comprise a single compound or mixtures thereof with other compounds or other compounds that inhibit cancer. The dosage unit may also comprise diluents, extenders, carriers and the like. The unit may be in solid or gel form, such as pills, tablets, capsules, liposomes and the like, or in liquid form suitable for oral, rectal, topical, intravenous injection or parenteral administration, or injection into or around the tumor.
F. DOSAGE SUPPLY FORMS Benzimidazoles and their derivatives, and chemotherapeutic agents are typically mixed with a pharmaceutically acceptable carrier. This carrier can be a solid or a liquid, or a liposome, and the type is generally selected based on the type of administration being used. The active agent can be co-administered in the form of a tablet or capsule, liposome, or as an agglomerated powder, or in liquid form. Examples of suitable solid carriers include lactose, sucrose, gelatin and agar. Capsules or tablets can be formulated easily, and can be easily made to swallow or chew; other solid forms include granules, and loose powders. The tablets may contain binders, lubricants, diluents, disintegrating agents, coloring agents, flavoring agents, flow inducing agents, and suitable melting agents. Examples of suitable liquid dosage forms include solutions or suspensions in water, pharmaceutically acceptable oils and fats, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and / or suspensions reconstituted from non-effervescent granules, and effervescent preparations reconstituted from effervescent granules. Such liquid dosage forms may contain, for example, solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and suitable melting agents. Oral dosage forms optionally contain flavors and coloring agents. Parenteral and intravenous forms would also include minerals and other materials to make them compatible with the type of injection or delivery system selected. Specific examples of acceptable pharmaceutical carriers and excipients that can be used to formulate the oral dosage forms of the present invention are described in US Patent No. 3,903,297 issued to Robert, published September 2, 1975. The techniques and compositions to make the dosage forms useful in the present invention are described in the following references: 7 Modern Pharmaceutics, Chapters 9 and 10 (Banker & amp;; Rhodes, Editors, 1979); Lieberman et al., Pharmaceutical Dosage Forms: Tablets (1981); and Ansel, Introduction to Phar aceutical Dosage Forms 2nd Edition (1976).
G. METHOD OF TREATMENT The method of treatment can be any suitable method that is effective in the treatment of the cancer type or particular tumor that is being treated. The treatment may be oral, rectal, topical, parenteral or intravenous administration, or by injection into the tumor and the like. The method of applying an effective amount also varies, depending on the tumor that is being treated. It is believed that parenteral treatment by intravenous, subcutaneous or intramuscular application of the benzimidazole compounds, formulated with an appropriate carrier, an additional compound or compounds that inhibit cancer, or diluent to facilitate the application will be the preferred method of administering the compounds to warm-blooded animals. Preferably, the chemotherapeutic agent is administered first, to reduce the size of the cancer or the mass of the tumor significantly. Usually this will take from 3 to about 14 days. The reduction in the tumor or concentration of cancer cells will be less than 50% of the original concentration. Radiation therapy can be used in conjunction with the. chemotherapeutic treatment. Once the tumor has been reduced, benzimidazole is administered. Due to the relative safety of this material, it can be administered for 14 days to 365 days, when needed, to maintain its effectiveness in reducing the resurgence of cancer. The following example is illustrative, and is not intended to be limiting of the invention.
Example 1 In a mouse model for breast cancer, cytoxan was administered to the animals to significantly reduce the tumor mass. Carbendazim was administered to the mice at 4,000, 5,000 and 6,000 mg / kg of body weight in a separate leg. The tumor continued to decrease in size, and its resurgence was limited even after 180 days, with the treatment of carbendazim. The growth was dependent on the dose. The control treated with cytoxan had a resurgence of the tumor after 100 days; and when stimulated with estrogen on day 115, it had a rapid resurgence. Even with estrogen stimulation, animals treated with carbendazim did not have a significant change in tumor mass. After 130 days, carbendazim was administered to the mice (at 4,000, 5,000 and 6,000 mg / kg body weight) who had been treated with cytoxan. The tumor continued to decrease in size, and resurgence was limited even after 180 days.
Claims (10)
- RE IV INDICATIONS 1. A medicine package for treating cancer, characterized in that it comprises combining two drugs in a kit form, the first drug is a safe and effective amount of a chemotherapeutic agent, which is in such a dosage that it is first administered for reducing cancer significantly, and wherein the second medicament is a safe and effective amount of a second pharmaceutical composition used to continue treating the cancer, comprising a benzimidazole selected from the group consisting of: "£ where * X is hydrogen, halogen, alkyl of less than 7 carbon atoms, or alkoxy of less than 7 carbon atoms, n is a positive integer less than 4, and is hydrogen, chlorine, nitro, methyl or ethyl, and R is hydrogen, or CONHR3, wherein R3 is alkyl of less than 7 carbon atoms, or an alkyl group having from 1 to 8 carbon atoms, and R2 is 4-thiazolyl or NHCOORx, wherein Rx is an aliphatic hydrocarbon of less than 7 carbon atoms, or the pharmaceutically acceptable inorganic or inorganic acid addition salts.
- 2. A kit according to claim 1, characterized in that the kit contains from about 0.5 mg / kg of body weight to about 400 mg / kg of body weight of the chemotherapeutic agent drug, and from about 2 mg / kg of weight body weight to about 400 mg / kg body weight of the benzimidazole medication.
- 3. A kit according to claim 1 or 2, characterized in that the benzimidazole medicament is selected from the group consisting of those having the formula: wherein R is hydrogen, and R2 is selected from the group consisting of NHCOORi, wherein Ra is methyl, ethyl or isopropyl, and pharmaceutically acceptable acid addition salts with both organic and inorganic acids.
- 4. A kit according to claim 1, 2 or 3, characterized in that the chemotherapeutic agent medicament is selected from the group consisting of Agents that interact with DNA, Antimetabolites or Agents that interact with Tubulin.
- 5. A kit according to claim 4, characterized in that the chemotherapeutic agent medicament is selected from the group consisting of Asparaginase, Hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine; Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, and Plcamidine.
- 6. A kit according to claim 4, characterized in that the drug of chemotherapeutic agent is selected from the group consisting of Methotrexate, Fluorouracil, Fluorodeoxyuridine, CB3717, Azacitidine, Cytarabine, Floxuridine, Mercaptopurine, 6-Thioguanine, Fludarabine, Pentostatin, Cytarabine, and Fludarabine
- 7. A kit according to claim 4, 5 or 6, characterized in that the chemotherapeutic agent medicament is in the form of a liposome.
- 8. A kit according to claim 7, characterized in that the benzimidazole medicament is in a liquid form selected from the group consisting of aqueous solutions, alcohol solutions, emulsions, suspensions, and reconstituted suspensions from non-effervescent and effervescent preparations, and suspensions. in pharmaceutically acceptable fats or oils.
- 9. A kit according to claim 7, characterized in that the chemotherapeutic agent medicament is selected from Taxol or Cisplatin, and wherein the second medicament is a pharmaceutical composition comprising 2-methoxycarbonylaminobenzimidazole or the pharmaceutically acceptable organic or inorganic acid addition salts. acceptable therefrom, and wherein the kit is for treating breast cancer in warm-blooded mammals.
- 10. A kit according to claim 9, characterized in that the chemotherapeutic agent medicament is in a dosage form for a treatment from 3 to 14 days, and wherein the 2-methoxycarbonylaminobenzimidazole is in a dosage for about 3 days to about 365 days .
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08788482 | 1997-01-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99006961A true MXPA99006961A (en) | 2000-01-01 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0956017B1 (en) | Benzimidazole-2-carbamates for the treatment of viral infections and cancer | |
AU729099B2 (en) | Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator | |
US6090796A (en) | Pharmaceutical composition for inhibiting the growth of cancers | |
EP0821586B1 (en) | A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers | |
US6251870B1 (en) | Pharmaceutical composition for inhibiting growth of cancers | |
MXPA98000998A (en) | Use of fluconazole to inhibit the growth of cance | |
MXPA97007809A (en) | A pharmaceutical composition containing benzymidazole to inhibit the growth of cance | |
MXPA98000945A (en) | Use of griseofulvine to inhibit cancer growth | |
EP0841914A2 (en) | Use of griseofulvin for inhibiting the growth of cancers | |
MXPA98000944A (en) | Use of derivatives of 1h-1,2,4-triazol to inhibit the growth of cance | |
US20010053773A1 (en) | Method for inhibiting the growth of cancers | |
US20010041678A1 (en) | Compositions and methods for treating cancer | |
MXPA99006961A (en) | Kit for inhibiting the growth of cancers, comprising a chemotherapeutic agent and a benzimidazole, and optionally a potentiator | |
AU763272B2 (en) | Benzimidazole-2-carbamates for the treatment of viral infections and cancer |